Exclusive: Nearly Five Years Before BMS Voluntarily Opened Up Myeloma Drug Network, HRSA Told Celgene it “Must Ensure” Entities Could Buy at 340B Price

Bristol Myers Squibb said Jan. 14 it voluntarily will let 340B covered entities buy Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through specialty pharmacies in the company's limited distribution network for the drugs. BMS acquired the drugs in 2019 when it acquired Celgene. In 2017, HRSA told Celgene it had to ensure that 340B entities could buy the drugs at 340B price through the same limited distribution network.

The U.S. Health Resources and Services Administration (HRSA) told drug manufacturer Celgene nearly five years ago the company “must ensure” that covered entities could buy its cancer drugs Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through Celgene’s limited

Read More »
Read More »

Health Center Opposes AstraZeneca’s Motion to Pause 340B Dispute Resolution Proceedings Over Company’s Contract Pharmacy Policy

A Vermont health center asked a 340B dispute resolution panel to reject AstraZeneca's motion to stay the proceedings.

A Vermont community health center that co-initiated 340B administrative dispute resolution (ADR) proceedings against AstraZeneca over its conditions on 340B contract pharmacy yesterday asked the panel hearing its claim to deny the drug company’s motion to stay the proceedings.

Little

Read More »
Read More »

Three Drug Makers, Including Two with Contract Pharmacy Restrictions, Post 340B Refund Notices

Bristol Myers Squibb, Novo Nordisk, and Ipsen Biopharmaceuticals notified 340B covered entities this week about refunds for charges above 340B ceiling prices.

Three drug manufacturers—including two that have imposed conditions on 340B contract pharmacy—posted public notices this week to 340B covered entities about refunds for charges above 340B ceiling prices.

Bristol Myers Squibb (BMS) and Novo Nordisk’s notices came to light yesterday

Read More »
Read More »

With Public Health Emergency Extended, 340B Flexibilities to Continue

340B program flexibilities will continue for another 90 days under the latest extension of the COVID-19 national public health emergency.

340B program flexibilities will continue under the eighth 90-day extension of the COVID-19 national public health emergency (PHE) late last week.

U.S. Health and Human Services (HHS) Secretary Xavier Becerra renewed the PHE on Friday, Jan. 14.

In

Read More »
Read More »

In Big Win for Pharmacy Groups, CMS Proposes Significant Changes to Medicare Part D Clawbacks

CMS wants to change Medicare Part D rules to rein in PBMs' controversial practice of clawing back drug payments to pharmacies after point of sale.

The Centers for Medicare & Medicaid Services (CMS) yesterday proposed changing Medicare Part D rules to curb plan sponsors and pharmacy benefit managers’ skyrocketing use of direct and indirect renumeration fees (DIR)—PBMs’ controversial practice of clawing back drug payments to

Read More »
Read More »

Judge Denies Calif. 340B Health Centers’ Motion to Halt State Medicaid Drug Payment Change

California health centers say they will continue to fight against the transfer of state Medicaid managed care drug coverage to Medicaid fee for service, despite being denied a temporary restraining order against the change.

A federal judge in Sacramento, Calif., late yesterday declined to stop California Medicaid’s transfer of managed care drug coverage to Medicaid fee for service that took effect on Jan. 1. Health centers enrolled in the 340B drug pricing program pledged

Read More »
Read More »

Carole Johnson Takes Charge of HRSA and the 340B Program

Carole Johnson's tenure as HRSA administrator officially began this week Tuesday.

The U.S. Health Resources and Services Administration (HRSA), the agency that runs the 340B drug pricing program, has a permanent leader again for the first time in almost a year.

Carole Johnson started in her position as HRSA administrator on

Read More »
Read More »

Biden Axing Trump’s “Most Favored Nation” Drug Pricing Rule that 340B Entities and Pharma Both Disliked

The Biden administration is rescinding ex-President Trump's unimplemented most favored nation drug pricing rule, which was disliked by 340B entities and drug manufacturers.

The Biden administration is rescinding an unimplemented Trump-era regulation that would have pegged Medicare Part B drug reimbursement for 50 expensive, physician-administered drugs on the lowest price that drug manufacturers provide in similar countries.

The U.S. Centers for Medicare &

Read More »
Read More »

HRSA Adds Three Days to 1Q 340B Registration Period

The first 340B covered entity registration period of the year will be Jan. 1-18, 2022, for an effective start date of April 1, 2022.

The first 340B covered entity registration period of the year will be Jan. 1-18, 2022, for an effective start date of April 1, 2022.

Eligible hospitals, health centers, clinics, and their child sites and contract pharmacies registered during the period

Read More »
Read More »

More Than 850 Hospitals Ask Feds to Appeal Judge’s 340B Contract Pharmacy Ruling

850+ hospitals in the 340B program sent the HHS secretary a letter yesterday asking the government to appeal a judge’s 340B contract pharmacy ruling.

Just over 850 hospitals in the 340B program asked the federal government yesterday to appeal a judge’s Nov. 5 ruling that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and others use contract pharmacies. They

Read More »
Read More »
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live